TRAIL分子靶点在肺癌治疗中的研究及应用
被引量:3
Research Advance of TRAIL Molecular Target in the Therapy of Lung Cancer
摘要
目前肺癌的发病率在全球范围内呈持续上升的趋势。在中国,肺癌的发病率和死亡率在所有肿瘤中是最高的。肺癌患者中,只有30%的非小细胞肺癌可以通过外科手术切除,但手术后5年存活率很低,生活质量也不高,晚期不能手术的患者通常只能采用常规化疗或放疗,毒副作用大,疗效不理想。因此,寻找新的肺癌治疗手段是目前亟待解决的难题。
出处
《中国肺癌杂志》
CAS
2009年第3期252-255,共4页
Chinese Journal of Lung Cancer
基金
江苏省自然科学基金(No.BS2007025)资助~~
参考文献22
-
1Wiley SR, Schooley K, Smolak PJ. Identification and characterization of a new member of the TNF family that induees apoptosis. Immunity, 1995, 3(6): 673- 682.
-
2Pan G, O'Rourke K, Chinnaiyan AM, et al. The receptor for the cytotoxic ligand TRAIL. Science, 1997,276(5309): 111-113.
-
3Pan G, Ni J, Wei YF, et al. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science, 1997, 277(5327): 815-818.
-
4Marsters SA, Sheridan JP, Pitti RM, et al. A novel receptor for Apo2L/ TRAIL contains a truncated death domain. Curr Biol, 1997, 7(12): 1003-1006.
-
5Emery JG, McDonnell P, Burke MB, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem, 1998, 273(23): 14363-14367.
-
6Trabzuni D, Famulski KS, Ahmad M. Functional analysis of tumor necrosis factor-ct-related apoptosis-inducing ligand (TRAIL): cysteine-230 plays a critical role in the homotrimerization and biological activity of this novel tumoricidal cytokine. Biol Chem, 2000, 350(2): 505-510.
-
7Buchsbaum D J, Zhou T, Lobuglio A F, et al. TRAIL receptor-targeted therapy. Future Oncol, 2006, 2(4): 493-508.
-
8Zhang L, Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther, 2005, 12(3): 228-237.
-
9Ki M Kim, Yong J Lee. Amiloride augments TRAIL-induced apoptotic death by inhibiting phosphorylation of kinases and phosphatases associated with the P13K-Akt pathway. Oncogene, 2005, 24(22): 355-366.
-
10Puduvalli VK, Sampath D, Bruner JM, et al. TRAIL-induced apoptosis in gliomas is enhanced by Akt-inhibition and is independent of JNK activation. Apoptosis, 2005, 10(1): 233-243.
二级参考文献28
-
1Xiao-Chao Wei Xin-Juan Wang Kai-Chen Lei Zhang Yu Liang Xin-Li Lin Department of Biochemistry and Molecular Biology,Peking University Health Science Center,Beijing 100083,ChinaProtein Studies,Oklahoma Medical Research Foundation,Oklahoma City,OK 73104,USA.Killing effect of TNF-related apoptosis inducing ligand regulated by tetracycline on gastric cancer cell line NCI-N87[J].World Journal of Gastroenterology,2001,7(4):559-562. 被引量:11
-
2Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity,1995,3(6):673-682.
-
3Odoux C, Albers A, Amoscato AA, et al. TRAIL, FasL and a blocking anti-DR5 antibody augment paclitaxel-induced apoptosis in human non-small-cell lung cancer. Int J Cancer,2002,97(4):458-465.
-
4Keane MM, Ettenberg SA, Nau MM, et al. Chemotherapy aug-ments TRAIL-induced apoptosis in breast cell lines. Cancer Res,1999,59(3):734-741.
-
5Lacour S, Hammann A, Wotawa A, et al. Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis. Cancer Res,2001,61(4):1645-1651.
-
6Aggarwal BB, Bhardwaj U, Takada Y. Regulation of TRAIL-induced apoptosis by ectopic expression of antiapoptotic factors. Vitam Horm,2004,67:453-483.
-
7Spierings DC, de Vries EG, Timens W, et al. Expression of TRAIL and TRAIL death receptors in stage Ⅲ non-small cell lung cancer tumors. Clin Cancer Res,2003,9(9):3397-3405.
-
8Abou El Hassan MA, Mastenbroek DC, Gerritsen WR, et al. Overexpression of Bcl2 abrogates chemo- and radiotherapy-induced sensitisation of NCI-H460 non-small-cell lung cancer cells to adenovirus-mediated expression of full-length TRAIL. Br J Cancer,2004,91(1):171-177.
-
9Yamanaka T, Shiraki K, Sugimoto K, et al. Chemotherapeutic agents augment TRAIL-induced apoptosis in human hepatocellular carcinoma cell lines. Hepatology,2000,32(3):482-490.
-
10Liu W, Bodle E, Chen JY, et al. Tumor necrosis factor-related apo-ptosis-inducing ligand and chemotherapy cooperate to induce apoptosis in mesothelioma cell lines. Am J Respir Cell Mol Biol,2001,25(1):111-118.
共引文献9
-
1张梅春,赵子文,刘朝晖,曾军,何卫国.重组人可溶性凋亡配体相关蛋白联合顺铂抑制肺癌裸鼠移植瘤的生长[J].实用医学杂志,2007,23(3):301-303. 被引量:3
-
2任满意,隋树建,张运,许复郁,马伟红.TRAIL及其受体DR5参与动脉粥样硬化的发生[J].基础医学与临床,2008,28(5):487-491. 被引量:2
-
3王爽,齐玲,金宏,张以忠,曹志友.肿瘤坏死因子相关凋亡诱导配体联合化疗药物对非小细胞肺癌细胞的作用机制研究[J].中国实验诊断学,2011,15(6):1000-1001. 被引量:4
-
4王文苹,季旭明,欧阳兵,王中霞,于华芸,吴智春.逆转肺癌多药耐药的研究进展[J].世界中西医结合杂志,2011,6(9):820-822. 被引量:4
-
5刁智娟,朱洁卿,史娟,郑德先.TRAIL对CIA小鼠脾细胞表达Th1/Th2细胞因子的影响[J].基础医学与临床,2011,31(12):1330-1334. 被引量:1
-
6杨艳明,刘林林,刘念,王志成.辐射诱导的重组载体pEgr1-hsTRAIL对肺腺癌A549细胞的生长抑制作用[J].吉林大学学报(医学版),2012,38(3):398-403. 被引量:1
-
7关锋,龚平生,王志成,刘扬,龚守良.肿瘤坏死因子相关凋亡配体在肿瘤放射治疗中的作用[J].中华放射医学与防护杂志,2014,34(3):231-234. 被引量:3
-
8张梅春,曾军,赵子文,刘朝晖.重组人肿瘤坏死因子相关凋亡诱导配体对人肺腺癌A549细胞裸鼠移植瘤内survivin基因表达的影响[J].中国基层医药,2015,22(2):203-207.
-
9陈文庆,闫松,蔡三立,刘刚.非小细胞肺癌细胞对肿瘤坏死因子相关凋亡诱导配体耐药机制分析[J].中国现代医药杂志,2015,17(4):55-56. 被引量:1
同被引文献7
-
1王晓光,罗荣城.抗肿瘤新生血管靶向治疗进展[J].临床肿瘤学杂志,2006,11(2):155-158. 被引量:7
-
2胡雪君,宋娜,刘云鹏,马艳菊,郝艳艳,康健.EGFR、VEGF和COX-2在非小细胞肺癌中的表达和意义[J].实用肿瘤杂志,2007,22(3):209-213. 被引量:20
-
3张军华,陈海泉.青年人原发性肺癌临床特点及诊治的研究进展[J].中国癌症杂志,2008,18(6):470-473. 被引量:12
-
4Xi Chen,Yi Ba,Lijia Ma,Xing Cai,Yuan Yin,Kehui Wang,Jig ang Guo,Yujing Zhang,Jiangning Chen,Xing Guo,Qibin Li,Xiaoying Li,Wenjing Wang,Yan Zhang,Jin Wang,Xueyuan Jiang,Yang Xiang,Chen Xu,Pingping Zheng,Juanbin Zhang,Ruiqiang Li,Hongjie Zhang,Xiaobin Shang,Ting Gong,Guang Ning,Jun Wang,Ke Zen,Junfeng Zhang,Chen-Yu Zhang.Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases[J].Cell Research,2008,18(10):997-1006. 被引量:1010
-
5吴学元,马巍,任国文,王振汉,张党风.肿瘤血管靶向治疗的研究进展[J].现代肿瘤医学,2009,17(1):121-125. 被引量:21
-
6张敬.CT灌注成像技术的临床应用[J].临床放射学杂志,2001,20(10):803-806. 被引量:41
-
7朱丹,赵宏伟,赵健琦,徐静波.肿瘤分子靶向药物阿帕替尼的临床研究进展[J].中国医院药学杂志,2017,37(2):194-198. 被引量:31
引证文献3
-
1牛晓晓,王秦秦.microRNA与肺癌[J].中国肺癌杂志,2010,13(4):380-385. 被引量:1
-
2李素素,肖建宇,张坤,刘竹君,郭翌,汪源源.基于CT灌注成像的肺癌疗效评估方法初探[J].肿瘤影像学,2018,27(3):280-285. 被引量:1
-
3李素素,肖建宇,张坤,刘竹君,郭翌,汪源源.基于CT灌注成像的肺癌疗效评估方法初探[J].肿瘤影像学,2018,27(4):302-306. 被引量:4
二级引证文献6
-
1黎赛(综述),胡彬(综述),李梨平(审校).儿童急性淋巴细胞白血病miRNA的研究进展[J].医学临床研究,2011,28(11):2159-2161.
-
2姜永清,高玉龙,陈斯,林立波,张大昌.多层螺旋CT平扫及灌注扫描对肺癌放疗疗效的评估价值[J].癌症进展,2019,17(6):666-668. 被引量:8
-
3郭俊涛,师志磊,王飞.多层螺旋CT平扫及灌注扫描对肺癌放疗疗效的评估价值[J].现代诊断与治疗,2019,30(22):4011-4012.
-
4王坤,王冠民,路志凯.动态增强CT对周围型肺癌的诊断价值[J].肿瘤研究与临床,2021,33(4):304-306. 被引量:12
-
5潘细根,郑悦,邵阳通,陈泓羽,陈福春.CT灌注成像参数在非小细胞肺癌靶向治疗疗效评估中的应用价值[J].中国现代医生,2021,59(28):118-121. 被引量:3
-
6耿鹤群,张志林,张晓辰,梁占东,李永,崔书君.多层螺旋CT灌注成像评价乳腺癌微血管生成的研究[J].中国临床保健杂志,2022,25(2):225-229. 被引量:5
-
1李秋萍,Alice Yuen Loke.癌症患者家庭照顾者的研究现状[J].中华护理杂志,2012,47(12):1132-1135. 被引量:49
-
2刘观成,何晓松.鼻咽癌肿瘤干细胞研究进展[J].现代医药卫生,2014,30(6):862-865. 被引量:1
-
3王敏,万强,赵永胜,周毅衡.伤寒菌实验室1~5年存活率及相关影响因素观察[J].中国卫生检验杂志,2008,18(2):367-368.
-
4张鑫,林碧华,李继霞,周克元.鼻咽癌肿瘤干细胞的研究进展[J].广东医学,2013,34(21):3343-3345. 被引量:8
-
5叶尔买克,张明鑫,王健生.结直肠癌动物模型研究进展[J].中国现代普通外科进展,2010,13(5):388-391. 被引量:7
-
6李兴华,屠振兴,龚燕芳,李兆申.人胰腺癌相关蛋白质的差异表达研究[J].中华消化杂志,2005,25(11):685-687.
-
7德国发明肺癌治疗新方法:纳米颗粒作为药物载体[J].广州医学院学报,2009,37(1):54-54.
-
8唐晓,黄孟军.中医药对慢性充血性心力衰竭心肌细胞凋亡的研究概况[J].河北中医,2008,30(1):105-106. 被引量:1
-
9陈孝平,张志伟,杨甲梅,沈锋.肝细胞肝癌外科治疗方法的选择[J].中华普通外科学文献(电子版),2010,4(1):22-22. 被引量:2
-
10陈孝平,张志伟,杨甲梅,沈锋.肝细胞肝癌外科治疗方法的选择[J].中华普通外科学文献(电子版),2008,2(6):6-6. 被引量:2